Notice Regarding Changes in Representative Directors, Organizational Restructuring, Executive Personnel Changes, and Personnel Transfers

Overview of Changes in Representative Directors and Organizational Restructuring

JCR Pharmaceuticals Co., Ltd. will implement changes in its representative directors effective April 1, 2026. Mr. Toru Ashida will assume the position of Chairman and Representative Director, Mr. Hiroyuki Sonoda will become President and Representative Director, and Mr. Shin Ashida will become Director and Founder. Additionally, the President’s Office and Advanced Biopharmaceutical Research Institute will be newly established as organizations directly overseen by the President, while a Regenerative Medicine Research Institute will be established within the Research Division, strengthening and expanding the organization. The Sales Division, Business Development Division, Corporate Strategy Division, and Administrative Division will also undergo name changes and organizational reorganization aimed at improving management efficiency.

Executive, Executive Officer, and General Personnel Changes

Effective April 1, 2026, personnel changes for directors and executive officers will be conducted. Mr. Andrea Spezzi will be promoted to Executive Director and Senior Executive Officer, and Mr. Hiroshi Honda will assume the roles of Senior Executive Officer, Head of the Administrative Division, and Director of the President’s Office, among other executive changes. General personnel changes include replacements and promotions of department heads and office managers across the Sales Division, Research Division, Production Division, Business Development Division, Corporate Strategy Division, and Administrative Division to strengthen organizational management.